Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 4/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | ANPEP | P15144 | 2/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.39 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.39 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.39 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29808940 | 1.00 | KDM1A (0.47) | KDM1AHTR2AANPEPSIGMAR1GRIN2D | |
| SCHEMBL1240196 | 1.00 | KDM1A (0.47) | KDM1AHTR2AANPEPSIGMAR1GRIN2D | |
| SCHEMBL14490666 | 1.00 | KDM1A (0.47) | KDM1AHTR2AANPEPSIGMAR1GRIN2D | |
| SCHEMBL1239150 | 1.00 | KDM1A (0.47) | KDM1AHTR2AANPEPSIGMAR1GRIN2D | |
| SCHEMBL1134242 | 1.00 | KDM1A (0.47) | KDM1AHTR2AANPEPSIGMAR1GRIN2D | |
| SCHEMBL1643076 | 1.00 | KDM1A (0.47) | KDM1AHTR2AANPEPSIGMAR1GRIN2D | |
| SCHEMBL8309860 | 1.00 | KDM1A (0.47) | KDM1AHTR2AANPEPSIGMAR1GRIN2D | |
| SCHEMBL29809038 | 1.00 | KDM1A (0.47) | KDM1AHTR2AANPEPSIGMAR1GRIN2D | |
| SCHEMBL6767234 | 1.00 | KDM1A (0.47) | KDM1AHTR2AANPEPSIGMAR1GRIN2D | |
| SCHEMBL1239149 | 1.00 | KDM1A (0.47) | KDM1AHTR2AANPEPSIGMAR1GRIN2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 181 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110255694-A | A kind of method of artificial synthesized redox mediators activation potassium permanganate degradation organic pollutants | 重庆大学 | 2019-09-20 | — | — | CN | claimed |
| US-9376447-B2 | Transfer hydrogenation of cyclopamine analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2016-06-28 | — | — | US | claimed |
| EP-2346848-B1 | QUINAZOLINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2013-02-27 | — | — | EP | claimed |
| US-8318749-B2 | Quinazoline derivatives as NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-11-27 | — | — | US | claimed |
| CN-1659154-B | Process for the preparation of amine stereoisomers | APSINTERM LLC | 2012-05-30 | — | — | CN | claimed |
| US-8188093-B2 | Pyrazinecarboxamide derivatives as HDL-cholesterol raising agents | HOFFMANN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | claimed |
| EP-2450350-A1 | 3-Pyridinecarboxamide and 2-pyrazinecarboxamide derivatives as HDL-cholesterol raising agents | F. Hoffmann-La Roche AG (CH) | 2012-05-09 | — | — | EP | claimed |
| US-20100267745-A1 | 3-Pyridinecarboxamide Derivatives as HDL-Cholesterol Raising Agents | ANDJELKOVIC MIRJANA | 2010-10-21 | — | — | US | claimed |
| US-20100125078-A1 | QUINAZOLINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2010-05-20 | — | — | US | claimed |
| EP-2074096-A1 | 3-PYRIDINECARBOXAMIDE AND 2-PYRAZINECARBOXAMIDE DERIVATIVES AS HDL-CHOLESTEROL RAISING AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-07-01 | — | — | EP | claimed |
| US-20050165240-A1 | Method of preparing amine stereoisomers | APSINTERM, LLC | 2005-07-28 | — | — | US | claimed |
| EP-1497272-A2 | METHOD OF PREPARING AMINE STEREOISOMERS | Apsinterm, LLC. (US) | 2005-01-19 | — | — | EP | claimed |
| JP-3547432-B2 | — | — | 2004-07-28 | — | — | JP | claimed |
| WO-2003091207-A2 | METHOD OF PREPARING AMINE STEREOISOMERS | APSINTERM, LLC. (US) | 2003-11-06 | — | — | WO | claimed |
| US-6184241-B1 | Aspartic protease inhibitors | KANSAS STATE UNIVERSITY RESEARCH FOUNDATION | 2001-02-06 | — | — | US | claimed |
| EP-0629210-B1 | PEPTIDE LINKAGE UNIT COMPRISING METHYLENE PHOSPHINIC ACID | SCRIPPS RESEARCH INST (US) | 1998-06-10 | — | — | EP | claimed |
| US-5563121-A | PHOSPHINATE METHYLENE AMMONIUM LINKAGE | THE SCRIPPS RESEARCH INSTITUTE (US) | 1996-10-08 | — | — | US | claimed |
| EP-0629210-A1 | PEPTIDE LINKAGE UNIT COMPRISING METHYLENE PHOSPHINIC ACID | THE SCRIPPS RESEARCH INSTITUTE (US) | 1994-12-21 | — | — | EP | claimed |
| WO-1993014114-A1 | PEPTIDE LINKAGE UNIT COMPRISING METHYLENE PHOSPHINIC ACID | THE SCRIPPS RESEARCH INSTITUTE (US) | 1993-07-22 | — | — | WO | claimed |
| WO-1993009134-A1 | PHOSPHONAMIDATE ESTER-CONTAINING PSEUDOPEPTIDES | THE SCRIPPS RESEARCH INSTITUTE (US) | 1993-05-13 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125078-A1 | QUINAZOLINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | SLC6A3, OPRK1, HTR3A | KDM1A 3480/4885HTR2A 132/4885ANPEP 2552/4885 |
| US-20050165240-A1 | Method of preparing amine stereoisomers | SRM, TST, SMOX | KDM1A 1638/4885HTR2A 397/4885ANPEP 814/4885 |
| US-20100267745-A1 | 3-Pyridinecarboxamide Derivatives as HDL-Cholesterol Raising Agents | CETP, APOB, LDLR | KDM1A 1583/4885HTR2A 1528/4885ANPEP 2199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.